XNASMLTX
Market cap3.32bUSD
Dec 24, Last price
52.67USD
1D
1.02%
1Q
3.66%
IPO
400.67%
Name
MoonLake Immunotherapeutics
Chart & Performance
Profile
Helix Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. The company was founded in 2020 and is based in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
Income | ||||
Revenues | ||||
Cost of revenue | 54,136 | 65,074 | 75,213 | |
Unusual Expense (Income) | ||||
NOPBT | (54,136) | (65,074) | (75,213) | |
NOPBT Margin | ||||
Operating Taxes | 94 | 36 | 5 | |
Tax Rate | ||||
NOPAT | (54,231) | (65,110) | (75,217) | |
Net income | (36,007) -44.18% | (64,506) 20.25% | (53,644) 58,954.16% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 482,454 | 4 | 28,263 | |
BB yield | -16.26% | 0.00% | -36.45% | |
Debt | ||||
Debt current | 1,306 | 154 | 15,000 | |
Long-term debt | 6,306 | 412 | ||
Deferred revenue | ||||
Other long-term liabilities | 583 | 282 | 240 | |
Net debt | (503,396) | (71,550) | (108,081) | |
Cash flow | ||||
Cash from operating activities | (42,778) | (55,894) | (35,175) | |
CAPEX | (285) | (16) | (51) | |
Cash from investing activities | (25,184) | (32,341) | (51) | |
Cash from financing activities | 479,702 | 119,693 | 43,263 | |
FCF | (57,848) | (65,396) | (75,047) | |
Balance | ||||
Cash | 511,008 | 72,115 | 8,039 | |
Long term investments | 115,043 | |||
Excess cash | 511,008 | 72,115 | 123,081 | |
Stockholders' equity | (96,478) | (60,426) | (53,701) | |
Invested Capital | 614,359 | 129,647 | 57,232 | |
ROIC | ||||
ROCE | ||||
EV | ||||
Common stock shares outstanding | 49,123 | 29,361 | 7,841 | |
Price | 60.39 475.14% | 10.50 6.17% | 9.89 -13.02% | |
Market cap | 2,966,510 862.23% | 308,294 297.57% | 77,545 -53.93% | |
EV | 2,480,929 | 256,613 | (30,464) | |
EBITDA | (54,123) | (65,061) | (75,208) | |
EV/EBITDA | 0.41 | |||
Interest | 592 | |||
Interest/NOPBT |